DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20163764

Loco-regionally advance breast cancer: evaluation of management of breast cancer with special reference to multimodal approach

Anshuman Panda, Subrata Kumar Das, Tapas Ranjan Gupta, Gouri Shankar Kesari, Sukanta Sen

Abstract


Background: Breast cancer is one of the most common human neoplasms, accounting for approximately one-quarter of all cancers in females worldwide and 27% of cancers in developed countries with a western lifestyle. The aims of this study were to evaluate the management of loco-regionally advanced carcinoma of breast with special reference to multimodal approach.

Methods: The study was conducted on patients with loco-regionally advanced carcinoma of breast, reporting for treatment in a large multi-specialty teaching institute. All patients of stage IIIB were initially treated with neo-adjuvant (induction) chemotherapy (3 cycles), except 4 patients in the study group offered surgery as initial treatment because of small tumor size with limited peu’d orange change in the skin. After this treatment all patients were reassessed with a thorough clinical examination and restaging work upto detect the response of the chemotherapy. All patients who achieved objective response (complete + partial) were offered surgery, followed by CT and RT.

Results: About 60% of the patients were in stage IIIB and 32% in stage IIIA. Majority of the tumors were in T4 category (64%). In 28% cases ipsilateral fixed lymph nodes were found. Histopathological examination revealed 76% (38) patients with infiltrating duct carcinoma, 4 patients (8%) had comedo carcinoma, 2 patients (4%) had lobular carcinoma, 2 patients (4%) had medullary carcinoma and 4 patients (8%) had mucinous carcinoma. Both nonresponsive (NR) and disease progression (DP) patients were in stage III B group. About 76.9% patients of stage IIIB (20) achieved partial response. Only 1 patient (33.3%) developed local recurrence after 10 months of completion of treatment. Median disease free survival (DFS) period of this group is 30.2 months. Recurrence rate is stage IIIA patients was 27.7% and in stage IIIB 37.5%. Maximum numbers of disease free patients were found in T3N1 group (85.7%). Patient with N2 and T4 disease chances of recurrence was more than N1 and T3 lesions.

Conclusions: Patients with LBAC who are able to complete treatment with chemotherapy, mastectomy, and postmastectomy radiation have a high probability of locoregional control. Neo-adjuvant chemotherapy can make inoperable locally advanced breast cancer operable and with the use of neo-adjuvant CT, breast conservation surgery is possible even in locally advanced breast cancer. Use of post-operative CT and RT can increase the disease free survival period. Use of multimodal treatment in the form of CT, surgery and radiotherapy can increase the disease free survival period in locally advanced breast cancer. The advent of successful multimodal regimens incorporating systemic treatment (chemotherapy or chemohormonal therapy) as well as local therapy (surgery and radiation) has significantly improved disease-free and overall survival as well as local-regional control. Longer follow-up of these conservatively treated patients will be needed, however, to determine whether local-regional control is preserved.


Keywords


Breast cancer, LABC, Multimodal approach, DFS, Outcome

Full Text:

PDF

References


Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ, editors. WHO Classification of Tumours of the Breast. Fourth ed. IARC; Lyon. 2012;4. ISBN.13.

Peter B, Bernard L. World Cancer Report. International Agency for Research on Cancer; WHO Press; Lyon, France. 2008.

Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33:315-8.

DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52-62.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on day/month/year.

American Cancer Society. Global cancer facts and figures, 2nd edn. American Cancer Society, Atlanta. 2011.

Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2015;72(2):333-8.

Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133-45.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.

Gupta S, Rao YN, Agarwal SP. Emerging strategies for cancer control for women in India. 50 Years of Cancer control in India. 2003. [Last accessed on 2016 Jun 30]. Available from http://www.medindia.net/education/MinistryofHealth/pg192to203.pdf .

Rao YN, Gupta S, Agarwal SP. National cancer control programme: Current status and strategies, 50 Years of cancer control in India; 2003. [Last accessed on 2016 Jul 14]. Available from http://www.medindia.net/education/MinistryofHealth/pg192to203.pdf .

Kamath R, Mahajan KS, Ashok L, Sanal TS. A Study on Risk Factors of Breast Cancer among Patients Attending the Tertiary Care Hospital, in Udupi District. Ind J Com Med. 2013;38(2):95-9.

Christiaens MR, Cataliotti L, Fentiman I. Comparison of the surgical procedures for breast conserving treatment of early breast cancer in seven EORTC centres. Eur J Cancer. 1996;32A:1866-75.

Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced non-inflammatory breast cancer. Surg Clin North Am. 1996;76(2):393-410.

Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, et al. Neo-adjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer. Cancer Res. 1987;47(14):3889-94.

Reddy RS, Reddy CR, Carcinoma of the breast: Its incidence and histological variants among South Indians. Ind J Med Sc. 1958;12:228.

Vinay K, Abul KA, Jon CA, Nelson F. Robbins and Cotran Pathologic Basis of Disease. Eight ed. Elsevier; Lyon. France. 2010.

Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The changing incidence of in situ and invasive ductal and lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1763-9.

Makki J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol. 2015;8:23-31.

Gupta JC. Breast lumps in Jabalpur area. Ind J Surg. 1983;268-73.

Pandya B, Wahane SM, Narang R. Clinical Profile of Fibroadenoma in Rural Vidharbha: A Geographical Entity in Central India. Inter J Rece Scient Rese. 2015;6(7):5117-20.

Ing R, Yio JH, Petrakis NL. Unilateral breast feeding and breast cancer. Lancet. 1972;2:124-7.

Jain P, Khanna S, Khanna NN. Clinicopathological correlation in carcinoma breast. Ind J Surg. 1989;25.

Crile G (Jr). Breast cancer- A personal perspective. Surg Clin North Am. 1984;64:1145-9.

Flisher B, Slack NH. Number of lymph nodes examined and prognosis of breast carcinoma. Surg Gynaecol Obstet. 1970;131:79-88.

Devita TV (Jr), Hellman, Rosenberg A. Cancer Principles and Practice of Oncology, 5th Ed. Lippincott –Raven. 1997;75(5):771-5.

Gelber RD. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients. Recent Results Cancer Res. 1984;96:102-9.

Haagensen CD. Diseases of the breast. Philadelphia; WB Saunders. 1971;622-30.

Haagensen C, Stout A. Carcinoma of the breast II: Criteria of operability. Ann Surg. 1943;118(6):1032-51.

Arnold D, Lesnick G. Survival following mastectomy for stage III breast cancer. Am J Surg. 1979;137(3):362-6.

Fracchia AA, Evans JF, Eisenberg BL. Stage III carcinoma of the breast. A detailed analysis. Ann Surg. 1980;192(6):705-10.

Rubens RD, Armitage P, Winter PJ, Tong D, Hayward JL. Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer. 1977;13(8):805-11.

Rao DV, Bedwinek J, Perez C, Lee J, Fineberg B. Prognostic indicators in stage III and localized stage IV breast cancer. Cancer. 1982;50(10):2037-43.

Lippman EM, Lichter SA, Danforth ND. Diagnosis and management of breast cancer. London, Philadelphia: WB Saunder Co. 1988;272-92.

Rubens RD, Sexton S, Tong D, Winter PJ, Knight RK, Hayward JL. Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer. 1980;16(3):351-6.

Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995;4(4):715-34.

Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 1994;73(2):362-9.

Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983;51(5):763-8.

Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008;72(2):474-84.